Heart Failure Clinical Trial
Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction
Summary
The global objective of this study is to determine the mechanisms of exercise intolerance and dyspnea on exertion (DOE) in patients with HFpEF and based on this pathophysiology, test whether specific exercise training programs (whole body vs single leg) will result in improved exercise tolerance.
Full Description
This will be a randomized, non-blinded prospective intervention testing the effects of two types of exercise training, whole body and isolated single leg, on HFpEF patients with either central or peripheral limitations to exercise training. Subjects will undergo baseline maximal exercise testing and invasive right heart catheterization to define exercise tolerance and pulmonary and cardiac pressures during exercise. Based on the results of baseline testing, subjects will be divided into either centrally limited, defined as excessive rise in pulmonary capillary wedge pressure more than 25 mmHg that decreases after administration of sub-lingual nitroglycerin resulting in improved exercise tolerance, or peripherally limited, defined as no improvement in exercise tolerance despite reduction in pulmonary capillary wedge pressure after sublingual nitroglycerin. After baseline testing, subjects will be randomized to either whole body cycle exercise supplemented with sublingual nitroglycerin to improve training responsiveness or isolated single leg exercise training for 4 months. After 4 months, subjects will repeat maximal exercise testing and invasive right heart catheterization to assess responses to 4 months of exercise training.
Eligibility Criteria
Inclusion Criteria:
signs and symptoms of heart failure
an ejection fraction > 0.50
objective evidence of diastolic dysfunction
Exclusion Criteria:
age < 60 years
BMI > 50 kg/m2
PDE5 inhibitor use
Severe valvular disease
Severe COPD
CKD 4 or higher
Contra-indication to MRI.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Dallas Texas, 75231, United States More Info
Principal Investigator
How clear is this clinincal trial information?